Protara Therapeutics to Participate in Upcoming Investor Conferences

Company Overview - Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and rare diseases [2] - The company's lead candidate, TARA-002, is an investigational cell-based therapy aimed at treating non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs) [2] - Protara is conducting an ongoing Phase 2 trial for TARA-002 in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to Bacillus Calmette-Guérin (BCG) treatment, as well as a Phase 2 trial in pediatric patients with LMs [2] Upcoming Events - Protara management will participate in the H.C. Wainwright & Co. 3 Annual BioConnect Investor Conference with a fireside chat scheduled for May 20, 2025, at 12:30 pm ET in New York [3] - The company will also take part in the TD Cowen 6 Annual Oncology Innovation Summit, which will be held virtually on May 27, 2025, at 1:30 pm ET [3] Additional Information - Protara is also developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who cannot meet their choline needs through oral or enteral routes [2] - Live webcasts of the investor conferences will be available on the company's website and archived for a limited time [1]